ALLANDER BIOTECHNOLOGIES, INC.

AURORA, CO

OncologyvaccineFiled/Approved

Compare Sign in to watch

What changed

Phase II trial registered: Tradipitant for Functional Dyspepsia

2d agoTrial registeredJul 16, 2026Source filing (opens the source filing in a new tab)

Momentum

96no change

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Filed/Approved

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

Grant
R35 · $441k · non-dilutive
Jun 1, 2026
UNIVERSITY OF ILLINOIS AT CHICAGO · PI WANG, XIAO · NIGMS · award ends Mar 31, 2031 · Dysbiosis, organ injury, and Systemic Inflammation
NIH RePORTER · NIH RePORTER 11257915 (opens the source filing in a new tab)
Trial
PHASE4 registered
May 25, 2026
Obesity & Overweight, Coronary Heart Disease · NOT_YET_RECRUITING · sponsor: China National Center for Cardiovascular Diseases · Effect of Mazdutide on Coronary Plaque in Patients With Coronary Atherosclerosis and Overweight or Obesity
ClinicalTrials.gov · NCT07657676 (opens the source filing in a new tab)
Trial
PHASE4 registered
Feb 25, 2026
Pregnancy, High Risk, Type 1 Diabetes · RECRUITING · sponsor: Ohio State University · Permissive Versus Strict Intrapartum Glucose Management in Type 1 Diabetes (PRISM-T1D)
ClinicalTrials.gov · NCT07293715 (opens the source filing in a new tab)
Grant
R44 · $1.2M · non-dilutive
Sep 15, 2025
ALLANDER BIOTECHNOLOGIES, INC. · PI YOUNG, CHRISTIAN · NCI · award ends Aug 31, 2027 · First-in-human clinical trial of proprietary oral gel to treat radiation-induced oral mucositis in cancer patients
NIH RePORTER · NIH RePORTER 11322800 (opens the source filing in a new tab)
Grant
R01 · $675k · non-dilutive
Jun 5, 2024
UNIVERSITY OF PENNSYLVANIA · PI WANG, XIAO · NICHD · award ends May 31, 2029 · Corrective editing to treat phenylketonuria
NIH RePORTER · NIH RePORTER 11332257 (opens the source filing in a new tab)
Trial
PHASE4 registered
Oct 19, 2023
Gestational Diabetes Mellitus, Pregnancy in Diabetic, Pregnancy, High Risk · COMPLETED · sponsor: Ohio State University · Patient Versus Provider-led Titration of Insulin for Glycemic Control in Gestational Diabetes (EMPOWER)
ClinicalTrials.gov · NCT05922033 (opens the source filing in a new tab)
Trial
PHASE2 registered
Feb 9, 2023
Functional Dyspepsia · ENROLLING_BY_INVITATION · sponsor: Xiao Jing (Iris) Wang · Tradipitant for Functional Dyspepsia
ClinicalTrials.gov · NCT05653310 (opens the source filing in a new tab)
Trial
NA registered
Jan 26, 2023
Bloating · COMPLETED · sponsor: Mayo Clinic · Treatment of Symptomatic Bloating Using a Novel Hypnotherapy Protocol
ClinicalTrials.gov · NCT05572606 (opens the source filing in a new tab)
Grant
P50 · $90k · non-dilutive
Sep 1, 2021
UNIVERSITY OF COLORADO DENVER · PI JIMENO, ANTONIO · NCI · award ends Aug 31, 2027 · Colorado Head and Neck Cancer SPORE
NIH RePORTER · NIH RePORTER 11212247 (opens the source filing in a new tab)
Grant
P50 · $313k · non-dilutive
Sep 1, 2021
UNIVERSITY OF COLORADO DENVER · PI JIMENO, ANTONIO · NCI · award ends Aug 31, 2027 · Colorado HNC SPORE Administrative Core
NIH RePORTER · NIH RePORTER 11180112 (opens the source filing in a new tab)
Grant
P50 · $347k · non-dilutive
Sep 1, 2021
UNIVERSITY OF COLORADO DENVER · PI WANG, XIAO-JING · NCI · award ends Aug 31, 2027 · Treating recurrent HNSCC with radiation and dual TGF-Beta/PD-L1.
NIH RePORTER · NIH RePORTER 11180120 (opens the source filing in a new tab)
Grant
P50 · $2.0M · non-dilutive
Sep 1, 2021
UNIVERSITY OF COLORADO DENVER · PI JIMENO, ANTONIO · NCI · award ends Aug 31, 2027 · Colorado Head and Neck Cancer SPORE
NIH RePORTER · NIH RePORTER 11180111 (opens the source filing in a new tab)
Grant
P50 · $370k · non-dilutive
Sep 1, 2021
UNIVERSITY OF COLORADO DENVER · PI JIMENO, ANTONIO · NCI · award ends Aug 31, 2027 · Targeting eEF2 with the protein translation elongation inhibitor SVC112 in head and neck squamous cancer
NIH RePORTER · NIH RePORTER 11180123 (opens the source filing in a new tab)

How this crosswalk was built

Confidence 100%Edges merged automatically, not yet reviewed by a human

Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
new_entity links the grant record at 0.33semantic similarity 87% · same therapeutic area

Links score at or above 0.86 to merge automatically. Anything below that and above the review line goes to a human queue. Resolution is a judgment, and it can be wrong. How resolution works.

Event stream

Every scored event, newest first. This is what momentum is computed from.

Phase II trial registered: Tradipitant for Functional Dyspepsia
2d agoTrial registeredSource (opens the source filing in a new tab)
Filed/Approved trial registered: Effect of Mazdutide on Coronary Plaque in Patients With Coronary Atherosclerosis and Overweight or Obesity
4w agoTrial registeredSource (opens the source filing in a new tab)
NIH R01 · $0.7M · Corrective editing to treat phenylketonuria
7w agoGrant renewalSource (opens the source filing in a new tab)
NIH R35 · $0.4M · Dysbiosis, organ injury, and Systemic Inflammation
8w agoNew grantSource (opens the source filing in a new tab)
Filed/Approved trial registered: Permissive Versus Strict Intrapartum Glucose Management in Type 1 Diabetes (PRISM-T1D)
2mo agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: Permissive Versus Strict Intrapartum Glucose Management in Type 1 Diabetes (PRISM-T1D)
2mo agoTrial recruitingSource (opens the source filing in a new tab)
Study registered, no phase assigned: Treatment of Symptomatic Bloating Using a Novel Hypnotherapy Protocol
9mo agoTrial registeredSource (opens the source filing in a new tab)
Trial completed: Treatment of Symptomatic Bloating Using a Novel Hypnotherapy Protocol
9mo agoTrial completedSource (opens the source filing in a new tab)
NIH P50 · $0.1M · Colorado Head and Neck Cancer SPORE
10mo agoGrant renewalSource (opens the source filing in a new tab)
NIH P50 · $0.3M · Colorado HNC SPORE Administrative Core
10mo agoGrant renewalSource (opens the source filing in a new tab)
NIH P50 · $0.3M · Treating recurrent HNSCC with radiation and dual TGF-Beta/PD-L1.
10mo agoGrant renewalSource (opens the source filing in a new tab)
NIH P50 · $2.0M · Colorado Head and Neck Cancer SPORE
10mo agoGrant renewalSource (opens the source filing in a new tab)
NIH P50 · $0.4M · Targeting eEF2 with the protein translation elongation inhibitor SVC112 in head and neck squamous cancer
10mo agoGrant renewalSource (opens the source filing in a new tab)
NIH R44 · $1.2M · First-in-human clinical trial of proprietary oral gel to treat radiation-induced oral mucositis in cancer patients
10mo agoNew grantSource (opens the source filing in a new tab)
Filed/Approved trial registered: Patient Versus Provider-led Titration of Insulin for Glycemic Control in Gestational Diabetes (EMPOWER)
Jul 2025Trial registeredSource (opens the source filing in a new tab)
Trial completed: Patient Versus Provider-led Titration of Insulin for Glycemic Control in Gestational Diabetes (EMPOWER)
Jul 2025Trial completedSource (opens the source filing in a new tab)

Last disclosed raise

No Form D is on file, so there is no raise to model a runway from. That is why the runway reads “—” rather than a number. It does not mean the company has no money: grants, revenue and notes below the Form D threshold are all invisible here.

Something wrong on this page? The crosswalk is a judgment and we would rather hear it. Report a bad link.

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources

Grant to raise

R35 · $441k · non-dilutive

PHASE4 registered

PHASE4 registered

R44 · $1.2M · non-dilutive

R01 · $675k · non-dilutive

PHASE4 registered

PHASE2 registered

NA registered

P50 · $90k · non-dilutive

P50 · $313k · non-dilutive

P50 · $347k · non-dilutive

P50 · $2.0M · non-dilutive

P50 · $370k · non-dilutive